vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and National Storage Affiliates Trust (NSA). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $187.0M, roughly 1.9× National Storage Affiliates Trust). National Storage Affiliates Trust runs the higher net margin — 12.2% vs 8.6%, a 3.7% gap on every dollar of revenue. On growth, LivaNova PLC posted the faster year-over-year revenue change (12.1% vs -1.6%). National Storage Affiliates Trust produced more free cash flow last quarter ($299.8M vs $50.2M). Over the past eight quarters, LivaNova PLC's revenue compounded faster (10.6% CAGR vs -2.4%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
National Storage Affiliates Trust is a U.S.-headquartered real estate investment trust focused on self-storage assets. It owns, operates and acquires self-storage facilities across dozens of U.S. states, offering secure storage solutions for residential and commercial customers.
LIVN vs NSA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $187.0M |
| Net Profit | $30.9M | $22.9M |
| Gross Margin | 65.2% | 72.5% |
| Operating Margin | 11.8% | 20.2% |
| Net Margin | 8.6% | 12.2% |
| Revenue YoY | 12.1% | -1.6% |
| Net Profit YoY | -44.7% | 36.8% |
| EPS (diluted) | $0.57 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $360.9M | $187.0M | ||
| Q3 25 | $357.8M | $188.7M | ||
| Q2 25 | $352.5M | $188.8M | ||
| Q1 25 | $316.9M | $188.4M | ||
| Q4 24 | $321.8M | $190.1M | ||
| Q3 24 | $318.1M | $193.6M | ||
| Q2 24 | $318.6M | $190.4M | ||
| Q1 24 | $294.9M | $196.1M |
| Q4 25 | $30.9M | $22.9M | ||
| Q3 25 | $26.8M | $18.4M | ||
| Q2 25 | $27.2M | $19.5M | ||
| Q1 25 | $-327.3M | $13.0M | ||
| Q4 24 | $55.9M | $16.7M | ||
| Q3 24 | $33.0M | $18.7M | ||
| Q2 24 | $16.3M | $17.1M | ||
| Q1 24 | $-41.9M | $59.0M |
| Q4 25 | 65.2% | 72.5% | ||
| Q3 25 | 68.4% | 70.7% | ||
| Q2 25 | 67.8% | 70.5% | ||
| Q1 25 | 69.7% | 70.7% | ||
| Q4 24 | 68.2% | 72.5% | ||
| Q3 24 | 70.8% | 72.8% | ||
| Q2 24 | 68.7% | 72.6% | ||
| Q1 24 | 70.3% | 72.1% |
| Q4 25 | 11.8% | 20.2% | ||
| Q3 25 | 15.1% | 15.8% | ||
| Q2 25 | 15.4% | 16.5% | ||
| Q1 25 | 15.3% | 11.0% | ||
| Q4 24 | 11.5% | 14.5% | ||
| Q3 24 | 11.2% | 15.8% | ||
| Q2 24 | 12.6% | 17.2% | ||
| Q1 24 | 5.5% | 48.9% |
| Q4 25 | 8.6% | 12.2% | ||
| Q3 25 | 7.5% | 9.8% | ||
| Q2 25 | 7.7% | 10.3% | ||
| Q1 25 | -103.3% | 6.9% | ||
| Q4 24 | 17.4% | 8.8% | ||
| Q3 24 | 10.4% | 9.7% | ||
| Q2 24 | 5.1% | 9.0% | ||
| Q1 24 | -14.2% | 30.1% |
| Q4 25 | $0.57 | $0.23 | ||
| Q3 25 | $0.49 | $0.17 | ||
| Q2 25 | $0.50 | $0.19 | ||
| Q1 25 | $-6.01 | $0.10 | ||
| Q4 24 | $1.04 | $0.19 | ||
| Q3 24 | $0.60 | $0.18 | ||
| Q2 24 | $0.30 | $0.16 | ||
| Q1 24 | $-0.78 | $0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $23.3M |
| Total DebtLower is stronger | $376.1M | — |
| Stockholders' EquityBook value | $1.2B | $946.0M |
| Total Assets | $2.6B | $5.1B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $635.6M | $23.3M | ||
| Q3 25 | $646.1M | $26.3M | ||
| Q2 25 | $593.6M | $26.1M | ||
| Q1 25 | $738.4M | $19.3M | ||
| Q4 24 | $428.9M | $50.4M | ||
| Q3 24 | $346.4M | $69.9M | ||
| Q2 24 | $329.2M | $59.0M | ||
| Q1 24 | $309.2M | $64.2M |
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
| Q4 25 | $1.2B | $946.0M | ||
| Q3 25 | $1.2B | $973.1M | ||
| Q2 25 | $1.1B | $1.0B | ||
| Q1 25 | $1.0B | $1.0B | ||
| Q4 24 | $1.3B | $1.1B | ||
| Q3 24 | $1.3B | $986.9M | ||
| Q2 24 | $1.2B | $1.2B | ||
| Q1 24 | $1.2B | $1.3B |
| Q4 25 | $2.6B | $5.1B | ||
| Q3 25 | $2.6B | $5.1B | ||
| Q2 25 | $2.5B | $5.2B | ||
| Q1 25 | $2.6B | $5.3B | ||
| Q4 24 | $2.5B | $5.4B | ||
| Q3 24 | $2.5B | $5.4B | ||
| Q2 24 | $2.5B | $5.3B | ||
| Q1 24 | $2.5B | $5.4B |
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $338.5M |
| Free Cash FlowOCF − Capex | $50.2M | $299.8M |
| FCF MarginFCF / Revenue | 13.9% | 160.3% |
| Capex IntensityCapex / Revenue | 8.9% | 20.7% |
| Cash ConversionOCF / Net Profit | 2.67× | 14.79× |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | $541.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | $338.5M | ||
| Q3 25 | $85.1M | $100.2M | ||
| Q2 25 | $62.9M | $79.9M | ||
| Q1 25 | $24.0M | $85.6M | ||
| Q4 24 | $78.7M | $363.1M | ||
| Q3 24 | $51.0M | $105.7M | ||
| Q2 24 | $43.4M | $83.2M | ||
| Q1 24 | $10.0M | $94.0M |
| Q4 25 | $50.2M | $299.8M | ||
| Q3 25 | $62.2M | $88.0M | ||
| Q2 25 | $47.8M | $73.8M | ||
| Q1 25 | $13.2M | $79.9M | ||
| Q4 24 | $68.3M | $344.4M | ||
| Q3 24 | $32.8M | $101.8M | ||
| Q2 24 | $31.2M | $79.5M | ||
| Q1 24 | $3.6M | $88.6M |
| Q4 25 | 13.9% | 160.3% | ||
| Q3 25 | 17.4% | 46.6% | ||
| Q2 25 | 13.6% | 39.1% | ||
| Q1 25 | 4.2% | 42.4% | ||
| Q4 24 | 21.2% | 181.2% | ||
| Q3 24 | 10.3% | 52.6% | ||
| Q2 24 | 9.8% | 41.7% | ||
| Q1 24 | 1.2% | 45.2% |
| Q4 25 | 8.9% | 20.7% | ||
| Q3 25 | 6.4% | 6.5% | ||
| Q2 25 | 4.3% | 3.2% | ||
| Q1 25 | 3.4% | 3.0% | ||
| Q4 24 | 3.2% | 9.8% | ||
| Q3 24 | 5.7% | 2.0% | ||
| Q2 24 | 3.8% | 1.9% | ||
| Q1 24 | 2.2% | 2.7% |
| Q4 25 | 2.67× | 14.79× | ||
| Q3 25 | 3.18× | 5.44× | ||
| Q2 25 | 2.32× | 4.10× | ||
| Q1 25 | — | 6.59× | ||
| Q4 24 | 1.41× | 21.70× | ||
| Q3 24 | 1.55× | 5.65× | ||
| Q2 24 | 2.65× | 4.88× | ||
| Q1 24 | — | 1.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
NSA
Segment breakdown not available.
